Including the Regulatory Perspective From the FDA

22-25 April, 2019 | Boston, MA

www.nash-summit.com

3rd Annual NASH Summit 2019

Accelerate the Successful Development of Your Non-Alcoholic Steatohepatitis (NASH) Therapeutic

Hear from 69 world-class experts including:

Jason Campagna
Senior Vice President & Global NASH Lead
Intercept

Frank Anania
Division of Gastroenterology & Inborn Errors Products
FDA

Jen-Chieh (Jay) Chuang
Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences & Research Scientist
Gilead Sciences

Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan

Dean Hum
Senior Executive Vice President & Chief Scientific Officer
Genfit

Jeanette Kusel
Director, NICE Scientific Advice
National Institute for Health & Care Excellence

Brent Tetri
Director, Division of Gastroenterology & Hepatology; Professor of Internal Medicine
Saint Louis University School of Medicine

Ritesh Shah
Commercial Development Lead, Internal Medicine
Pfizer

Becky Taub
Chief Medical Officer, Executive Vice President Research & Development
Madrigal Pharmaceuticals

Maria-Chiara Magnone
Vice President, Metabolic Complications
Janssen Research & Development

Peter Traber
Partner
Alacrita Consulting

Resat Cinar
Co-Chair NIH Fibrosis Scientific Interest Group
National Institutes of Health

Lead Partner:

ICON

Senior Partners:

PPD prosciento ADVISE • ADVANCE • ACHIEVE SIEMENS Healthineers

Program Partners:

Barc Lab HEPQUANT FUNCTION MATTERS KBI Syneos Health WuXiNextCODE

Tel: +1 617 455 4188 Email: info@hansonwade.com

Nonalcoholic Steatohepatitis (NASH) Group

hansonwade

Welcome to the World's Largest Gathering of NASH Drug Developers

Harnessing Understanding from Early Discovery to Commercialization

Now in its 3rd year, the NASH Summit in Boston is the industry's most comprehensive forum for advancing the development of successful NASH therapeutics.

Across 4 days of unparalleled content sharing and networking, 58 industry leaders will present actionable takeaways on the next 12 months of NASH drug development including: building the confidence of investors, patient recruitment for phase 3 and specific candidates as the backbone for combinations.

Join **300+ peers** from over **150 organizations** as this exclusively drug development driven conference equips your team with the connections and applicable insights you need to capture one of many market opportunities addressing NASH.

What Can You Expect?

- **300+** Attendees
- **150+** Organizations
- **69** Expert Speakers
- **3** Streams of Learning
- **2** Seminars
- **4** Workshop Discussions
- **12+** Hours of Networking
- **1** Keynote's & Networking Evening

Your Top 10 Takeaways From the Industry Leaders

1. **Benchmark a Comprehensive Understanding of the Competitive Clinical Trial Landscape**
   Hear uniquely unbiased perspectives on the current dynamics of the field and contextualize emerging candidates against your own pipeline

2. **Harness Machine Learning & Artificial Intelligence**
   Evaluate recent work on applying machine learning for NASH biomarker synthesis to optimize your own drug development-biomarker relationship in imaging analysis and patient stratification

3. **Strategize Commercial Success & Building Investor Confidence**
   Analyze commercial considerations, the pricing and reimbursement landscape, market development opportunities and delivering a cost-effective NASH treatment to plan your entrance to market

4. **Review the Current Non-Invasive Diagnostic Modalities**
   Contextualize the qualification of fit for purpose biomarkers and their success in drug development

5. **Critically Address the Bench to Bedside Translational Gap**
   Evaluate *ex vivo* modalities to better predict efficacy of your candidate and more confidently confirm rationale in human context

6. **Investigate Pharmacotherapy in the Context of Combinations**
   Review mechanisms of action addressing NASH and discuss the potential of combinations to most effectively address fibrosis

7. **Hear Case Studies & Anti-NASH Activity of Emerging Candidates**
   Evaluate data driven case studies to broaden your perspective on potential efficacy against NASH

8. **Contextualize the Relationship of NASH with Wider Liver & Cardiovascular Disease**
   Understand hepatocellular carcinoma as an extension of NASH and question NASH co-morbidity interactions

9. **Hear Clinical Advances of NASH Therapeutics in Phase 2 & Phase 3 Clinical Trials**
   Understand the patient recruitment strategies for phase 3 clinical trials and preparations for leading drugs as the backbones for combinations

10. **Understand the Regulators' & Payers' Perspectives**
    Hear from the FDA and NICE as they respectively review the latest regulatory guidelines and the protocol for payers' decisions when considering NASH therapeutics

Tel: +1 617 455 4188 **Email:** info@hansonwade.com
www.nash-summit.com Nonalcoholic Steatohepatitis (NASH) Group

hansonwade

What's New in 2019?

Fresh Content From Fresh Faces:

59 New speakers

22 New speaking companies

16 Drug Case Studies

Regulatory Perspective

Review the latest regulatory guidance with the FDA ahead of the latest round of phase 3 results.

Non-Invasive Biomarkers Deep Dive

Join the full seminar day dedicated to benchmarking and sharing the most innovative case studies set to unlock the next arsenal of NASH candidates. Chaired by **Jay Chuang (NASH, Fibrotic Diseases, Biomarker Sciences & Research Scientist at Gilead)** this focused seminar benchmarks the very latest from **NIMBLE, LITMUS** and innovations within imaging and serum biomarkers to **better inform your biomarker related strategies and support clinical program success.**

Commercial Leaders Day

Hear from marketing and commercial development leads as they share perspectives on strategizing considerations for commercialization, navigating market development, and building investor confidence in the crowded NASH landscape. Be part of the discussions taking place within this exclusively commercial stream and **map out the next step of your business development plan in NASH.**

Payer's Perspective

Investor Perspective

Keynotes & Networking Evening

Join us for an evening of networking and NASH keynote speakers, including our inaugural patient insights panel. Establish connections early on, contextualize conversations before the main sessions or just relax and enjoy the atmosphere. We're excited to host you all and celebrate the progress of drug development in the last 12 months.

Why You Should Attend the NASH Summit

"I immensely enjoyed the last three days. The format, location and event organization were excellent. I really don't have any suggestions for improvements as the right priorities seem to be in place....The NASH Summit provides the most comprehensive and up to date overview over this increasingly complex field. Organization, speaker selection and atmosphere on site were excellent"

UNIVERSITY OF TORONTO

"I appreciated the good mix of topics, even within each stream. It was good to hear about the work being done both in my focus area and other related fields and to network and have conversations with other companies/individuals doing that work, particularly with the mindset of combination therapies being likely in the future. Being able to engage in conversations about how that process will work and change processes across the board was helpful"

INDIGO BIOSCIENCES
The Nuclear Receptor Experts™

"Both the NASH Summits have been very well organized. I like that these are small gatherings. Allows a focussed discussion on NASH and chance to interact with key stakeholders"

Genentech
A Member of the Roche Group

"Even when I hear talks from people I already know- I still come away with new information. It is amazing how much you can take away from this conference"

GENFIT
TOWARDS BETTER MEDICINE

"Conference was a great networking event and chance to get up-to-date on science and technologies out there and form new connections in key leaders in the filed"

MedImmune
A member of the AstraZeneca Group

"Interaction in a less formal environment with pharma and active drug development programs"

Galectin Therapeutics

Your 69 Expert Speakers

Adil Mardinoglu
Professor of Systems Biology
Kings College London

Alistair Smith
Executive Medical Director
Syneos Health

Anthony Samir
Assistant Professor
Harvard Medical School

Becky Taub
Chief Medical Officer, Executive Vice President Research & Development
Madrigal Pharmaceuticals

Brent Tetri
Director, Division of Gastroenterology & Hepatology; Professor of Internal Medicine
Saint Louis University School of Medicine

Bryan Burkey
Head of Pharmacology
Zafgen

Cathleen Dohrn
Senior Scientific Director
Continuum Clinical

David Fraser
Chief Scientific Officer
NorthSea Therapeutics

Dawie Wessels
Chief Medical Officer
PPD

Dean Hum
Senior Executive Vice President & Chief Scientific Officer
Genfit

Donna Cryer
President & Chief Executive Officer
Global Liver Institute

Éric Lefebvre
Chief Medical Officer
Pliant Therapeutics

Frank Anania
Division of Gastroenterology & Inborn Errors Products
FDA

Greg Everson
Chief Executive Officer
HepQuant

Greg Tesz
Principal Scientist
Pfizer

Guodong Zhang
Director of Crown Bioscience Louisiana (CBLA)
Crown Bioscience

Gyongyi Szabo
Vice Chair for Research, Department of Medicine
University of Massachusetts Medical School



H. James Harwood
Adjunct Professor Department of Pathology
Wake Forest University School of Medicine

Isai Peimer
Biotech Analyst
Surveyor Capital

Jagpreet Chhatwal
Assistant Professor
Harvard Medical School

James Conway
Senior Scientist-Translational Bioinformatics
MedImmune

Jason Campagna
Senior Vice President & Global NASH Lead
Intercept

Jeffrey Gulcher
Chief Scientific Officer & Co-Founder
WuXi NextCODE

Jelena Mann
Professor of Epigenetics, Fibrosis Research Group
Newcastle University

Jen-Chieh (Jay) Chuang
Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences & Research Scientist
Gilead

Kelsey Retting
Associate Director, Tissue Platform Operations
Organovo

Jeanette Kusel
Director, NICE Scientific Advice
National Institute for Health & Care Excellence

Julia Brosnan
Senior Director, External Collaborations & Scientific Alliances
Pfizer

Laura Brattain
Research Scientist, Department of Radiology
Massachusetts General Hospital

Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan

Liat Hayardeny
Chief Scientific Officer
Galmed Pharmaceuticals

Linda Morrow
Vice President & Chief Medical Officer
ProSciento

Lou Griffel
Executive Director, Global Product Development
PPD

Maria-Chiara Magnone
Vice President, Metabolic Complications
Janssen Research & Development

Marko Korenjak
Vice President
European Liver Patients Association

Manu Chakravarthy
Chief Medical Officer & Senior Vice President
Axcella Health

Matthews Bradley
Founder, Chairman, President & Chief Technical Officer
SAJE Pharma

Michael Briggs
President & Chief Scientific Officer
Woodland Biosciences

Nathalie Belmonte
Vice President Product Development
Promethera Biosciences

Min Lu
Director, Head of Fibrosis
Morphic Therapeutics

Naim Alkhouri
Director of the Metabolic Health Center
Texas Liver Institute

Nicolas Guisot
Research Fellow
Redx Pharma

Nikolai Naoumov
Executive Director, Hepatology Sciences & Innovation
Novartis

Pablo Ortiz
Chief Executive Officer
OWL Metabolomics (in Partnership with BARC Lab)

Patrick Horn
Chief Medical Officer
Albireo Pharmaceuticals

Pascal Prigent
Executive Vice President, Commercial
Genfit

Peter Guzzo
Cofounder & Chief Executive Officer
ConSynance Therapeutics

Peter Caravan
Director of the Institute for Innovation in Imaging
Massachusetts General Hospital

Peter Traber
Partner
Alacrita Consulting

Pietro Scalfaro
Chief Medical Officer
Enyo Pharma

Pnina Fishman
Chief Executive Officer
CanFite BioPharma

Resat Cinar
Co-Chair NIH Fibrosis Scientific Interest Group
National Institutes of Health

Richard Lee
Director
Ionis Pharmaceuticals

Richard Torstenson
Independent Regulatory Advisor

Ritesh Shah
Commercial Development Lead, Internal Medicine
Pfizer

Robert Arch
Executive Director; Head, Liver Disease Program
China Novartis Institute for BioMedical Research



Roberto Calle
Executive Director, Internal Medicine Research Unit
Pfizer

Robert Riccio
Vice President, Clinical Development
Syneos Health

Speaker TBC
Stratified Medicine Scotland Innovation Centre

Santhosh Satapati
Senior Scientist, Cardiovasular Renal, Metabolic & Ophthalmic Diseases Division
Merck

Saswata Talukdar
Director – CardioMetabolic Discovery
Merck

Saurabh Gupta
Director – Translational Research & Early Clinical
Takeda

Suneil Hosmane
Executive Vice President-Strategic Development
Genfit

Star Seyedkazemi
Associate Vice President in Clinical Development
Allergan

Tony Wang
Chief Technology Officer
Kunming Biomed International

Wayne Eskridge
Chief Executive Officer
Fatty Liver Foundation

Weilin Xie
Senior Principal Scientist
Celgene

Tony Villiotti
President
NASH Education Corporation

Yury Popov
Assistant Professor of Medicine
Harvard Medical School

Agenda-at-a-Glance

Seminar Day
Monday April 22

Non-invasive Biomarkers Deep Dive

Commercial Leaders Day

Lunch & Networking

Non-invasive Biomarkers Deep Dive

Commercial Leaders Day

Keynotes & Networking Evening

Scientific Program, Day 1
Tuesday April 23

Plenary Stream

Speed Networking

Discovery Stream | Translational Stream | Clinical Stream

Lunch & Networking

Discovery Stream | Translational Stream | Clinical Stream

Plenary Stream

Scientific Poster Session

Scientific Program, Day 2
Wednesday April 24

Plenary Stream

Speed Networking

Discovery Stream | Translational Stream | Clinical Stream

Lunch & Networking

Plenary Stream

Discussions Day
Thursday April 25

Workshop A

Workshop C

Workshop B

Workshop D

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!" **AstraZeneca**

Seminar Day: Monday April 22

Non-Invasive Biomarkers Deep Dive

With an approved therapeutic getting nearer, this focused seminar is a series of talks dedicated exclusively for the leading minds in NASH biomarker research to evaluate and standardize non-invasive diagnostics that will shape next generations of research and development.

Chair: Jen-Chieh (Jay) Chuang
Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences & Research Scientist
Gilead

Non-Invasive Biomarkers: What Do We Have?

9.30 Review & Analysis of the Current Non-Invasive Diagnostic Modalities
Jen-Chieh (Jay) Chuang
Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences & Research Scientist
Gilead

9.45 LITMUS – Valorizing the European NAFLD Registry
- Highlighting the need for biomarkers in NAFLD drug development
- Outlining the contexts of use - diagnostic, prognostic and monitoring biomarkers
- Overviewing the value of public private partnerships in advancing biomarkers for NAFLD with LITMUS

Julia Brosnan
Senior Director, External Collaborations & Scientific Alliances
Pfizer

10.15 NIMBLE Project: Finding Non-Invasive Biomarkers for NASH (FNIH Biomarkers Consortium)
- Public/private partnerships and collaborative science
- Context of use and fit for purpose biomarkers
- The promise of non-invasive markers for NASH and how to get there

Roberto Calle
Executive Director, Internal Medicine Research Unit
Pfizer

10.45 Extended Q&A for NIMBLE & LITMUS

11.00 Morning Break & Networking

Commercial Leaders Day

A dedicated session for clinical leaders in NASH to hypothesize and clarify the challenges associated with commercialization and approval of candidates following the approval of preceding drugs.

Chair:
To Be Confirmed

Drug to Clinic: How Do We Get There?

9.30 Considerations of a Payer for Non-Alcoholic Steatohepatitis
- NICE UK's decision making process as the payer for the National Health Service (NHS) UK
- Payers' thoughts on use of surrogate endpoints
- Navigating long term uncertainty: predicting quality of life and survival
- Pricing to account for uncertainty and resource savings

Jeanette Kusel
Director, NICE Scientific Advice
National Institute for Health & Care Excellence

10.00 Future NASH Commercial Landscape
- Understanding the patient population and unmet need
- Evolving patient journey and treatment landscape
- Ensuring access to appropriate diagnostics and treatments

Ritesh Shah
Commercial Development Lead, Internal Medicine
Pfizer

10.30 Designing Clinical Trials in Pediatric NASH: From Patient Selection to Endpoints & Beyond
- Similarities and differences between pediatric and adult NASH
- Designing a successful NASH trial in children from a family to physician to industry perspectives

Naim Alkhouri
Director of the Metabolic Health Center
Texas Liver Institute

11.00 Morning Break & Networking

Technology Showcase: Quantifying Fibrosis Through Non-Invasive Diagnostics

11.45 Multiparametric Imaging: Translating Preclinical Observations into Human Trial

Noninvasive quantification of fibrosis holds value for future preclinical drug explorations and monitoring of response to therapy that would accelerate novel treatment evaluation. Leveraging current advancements with imaging in relation to liver fibrosis is pivotal to quantifying the disease non-invasively and subsequently improving vital patient recruitment and retention for clinical trials

This session will explore:

- Molecular magnetic resonance imaging (MRI) to quantify liver fibrosis and fibrogenesis
- Other noninvasive methods to estimate liver fibrosis
- Multiparametric imaging - translating preclinical observations into human trial

Peter Caravan
Director of the Institute for Innovation in Imaging
Massachusetts General Hospital
Bryan Fuchs
Assistant in Molecular Biology
Massachusetts General Hospital

Drug to Clinic: How Do We Get There? (Continued)

11.45 Potential Impact & Value of NASH Therapies

- What is the disease burden of NAFLD and NASH?
- What is the potential impact of NASH therapies on reducing disease burden and mortality?
- What is the potential cost-effectiveness of NASH therapies?

Jagpreet Chhatwal
Assistant Professor
Harvard Medical School

12.15 Panel Discussion: What Can We Understand About the Pricing & Reimbursement Landscape?

- What should be considered when strategizing the pricing and reimbursement landscape?
- Contextualizing the payers perspective for first approved therapies and considerations for candidates that follow

Jeanette Kusel
Director, NICE Scientific Advice
National Institute for Health & Care Excellence
Ritesh Shah
Commercial Development Lead, Internal Medicine
Pfizer
Pascal Prigent
Executive Vice President, Commercial
Genfit
Jagpreet Chhatwal
Assistant Professor
Harvard Medical School

12.45 Lunch & Networking

Innovations to Enhance the Utility of Biomarkers for Fatty & Fibrotic Liver Disease

1.45 Exploring the Translatability of NASH Biomarkers

- Exploring the utility of current non-invasive biomarkers for disease severity, patient stratification, early responsiveness and longitudinal monitoring in clinical trials

Saurabh Gupta
Director, Translational Research & Early Clinical Data
Takeda

2.15 Machine Learning for NASH Biomarkers

- Opportunities and challenges in AI for biomedicine
- Recent work on applying machine learning for NASH biomarker synthesis

Laura Brattain
Research Scientist, Department of Radiology
Massachusetts General Hospital

2.45 Developing an *In Vitro* Diagnostic Test (IVD) in Parallel to Advancing a Drug Candidate

- Primer on different types of diagnostic tests
- Overview of NASH diagnostic landscape
- Identifying biomarkers to aide in the diagnosis of NASH patients

Suneil Hosmane
Executive Vice President Strategic Development
Genfit

3.15 Chair's Summary
Jen-Chieh (Jay) Chuang
Nonalcoholic Steatohepatitis, Fibrotic Diseases, Biomarker Sciences & Research Scientist
Gilead

Insights into Investment & Market Development

1.45 Panel Discussion: How do we Build Investor Confidence in NASH Pipelines?

- Analyzing the NASH market landscape from an investor perspective
- Sharing insights into how to build investor confidence
- Lessons learnt from significant investments to date in NASH

Isai Peimer
Biotech Analyst
Surveyor Capital
Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan
Peter Traber
Partner
Alacrita Consulting

2.30 Chair's Summary

Keynotes & Networking Evening

Our inaugural Keynotes and Networking evening will welcome all NASH Summit attendees.

5.00 **Welcome**

5.15 **Inflammation as a Driver of NASH**

Gyongyi Szabo
Vice Chair for Research, Department of Medicine
University of Massachusetts Medical School

5.45 **Patient Insights on Education & Impact on Clinical Trials:**

A fireside chat with two NASH patients actively involved in education, screening and advocacy, focusing on how to improve trial participation and navigation of the health system across NASH specialists.

Moderated by:

Donna Cryer
President & Chief Executive Officer
Global Liver Institute

Patient Insights From:

Wayne Eskridge
Chief Executive Officer
Fatty Liver Foundation

Tony Villiotti
President
NASH Education Corporation

6.15 **Drinks & Speed Networking**

7.00 **Evening Concludes**

"I found the conference very interesting. It was well organized and I like that it was small because it fostered a lot of discussion. The networking periods were extremely helpful and the speed networking was the highlight of the conference. I would love to have done a second round to meet the rest of the people and hear more about their work"
MatTek Corporation

"Very targeted meeting filled with KOLs and industry leaders in this exciting field. Meeting organized and run better than any other conference I have attended"
IntelliCyt

Scientific Program: Tuesday April 23

Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan

7.50 Chair's Opening Remarks

Outlining Current Understanding & Gaps in Our Knowledge to Most Efficaciously Address NASH

Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan

8.00 What is the Future of NASH?
Overviewing areas of unmet need with emphasis on unchartered territory and addressing the associated high priority questions limiting drug development in these spaces including:
- Collaboration in NASH. How do we partner to advance the field?
- How do we meet the urgency of identifying biomarkers to diagnose patients with NASH and fibrosis at risk of disease progression?
- What can we expect from different agents targeting steatohepatitis and/or fibrosis?
- Are current surrogate endpoints aligned with stakeholders' expectations?
- Are combinations and cross-company collaborations the future of NASH therapy?

Brent Tetri
Director, Division of Gastroenterology & Hepatology; Professor of Internal Medicine
Saint Louis University School of Medicine

8.30 Keynote: Many Paths to NASH-Many Targets for Treatment
- NASH is a phenotype that likely results from different genetic, epigenetic and dietary exposures in different patients
- The underlying driver of hepatocellular injury and the resulting inflammation and fibrosis in NASH is an oversupply of fatty acids in hepatocytes
- Approaches to treatment include interventions that reduce energy intake, improve extrahepatic metabolism of fatty acids and glucose, decrease the generation of fatty acids in the liver, reduce the inflammatory wound response caused by lipotoxicity and reverse extracellular matrix deposition
- As new drugs are developed, future therapy for NASH will likely involve a multi-drug approach in addition to lifestyle modification that is rationally based on complementary pathways.

9.00 Strategies for Patient Identification, Access & Site Engagement in NASH Trials
- Outlining ICON's pre-screening strategy to respond to increased competition for NASH patients, coupled with high screen failure rates associated with this indication
- Discussing the details of the methodology and best practices of the pre-screening effort, together with potential areas for future focus

9.30 Speed Networking
This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the NASH field and establish meaningful business relationships.

10.15 Morning Break

Discovery Stream:	Translational Stream:	Clinical Stream:
Chair: H. James Harwood, Adjunct Professor Department of Pathology, **Wake Forest University School of Medicine**	Chair to be Confirmed	Chair: Peter Traber, Partner, **Alacrita Consulting**
Cross-Disciplinary Outlook on NASH Molecular Drivers & Targeting Them	**Critically Addressing the Bench to Bedside Translational Gap**	**Strategic Considerations for Phase 3 Clinical Trials**
10.45 Targeting the Wnt Pathway • Proving liver fibrosis is the most important histological feature that is associated with long term outcomes of NASH patients • Targeting the Wnt signaling pathway could potentially provide an important therapeutic intervention for liver fibrosis **Weilin Xie** Senior Principal Scientist **Celgene**	**10.45 Use of Precision Cut Liver Slices in the Modelling of Fibrosis** • Demonstrating the utility of precision cut liver slices (PCLS) retaining the structure and cellular composition of the native liver and therefore representing a much superior and improved system to study liver fibrosis compared to two-dimensional or mono/co-cultures of cells • Showcasing the Newcastle Fibrosis Research Laboratory (NFRG) bioreactor system that increases the healthy lifespan of PCLS which allows us to model fibrogenesis	**10.45 NASH, Now: Therapeutic Targets & the Competitive Clinical Trial Landscape** • Overview of clinical compounds being evaluated for NASH with emphasis on mechanistic differences • Evaluating regulatory guidance on development of NASH therapeutics with focus on histology versus non-invasive imaging in drug advancement

- Sharing data on testing the ability of clinically approved drugs to limit fibrosis in this model; as an example, nintedanib and obeticholic acid therapy limit fibrogenesis in PCLS
- Describing how this new bioreactor can be successfully used to model fibrogenesis and demonstrate efficacy of anti-fibrotic therapies

Jelena Mann
Professor of Epigenetics
Fibrosis Research Group
Newcastle University

- Discussing how current clinical experience and understanding can influence the next generation of R&D and commercialization decisions

Peter Traber
Partner
Alacrita Consulting

11.15 Rationale for the Use of Bile Acid Modulators for the Treatment of NASH

- Demonstrating preclinical data of bile acid modulators
- Reviewing literature and presenting an argument for the use of bile acid modulators against NASH

Patrick Horn
Chief Medical Officer
Albireo Pharma

11.15 HepaStem for the Treatment of Fibro-Inflammatory Liver Diseases

- Showing Hepastem as having multiple MoA of interest for NASH
- Presenting clinical data generated in ACLF patients
- HepaStem is developed in NASH indication (PhI/IIa)

Nathalie Belmonte
Vice President Product Development
Promethera Bioscience

11.15 Does Recruitment in NASH Trials Have to Behave like a Rare Disease?

- Exploring the trend and root causes of the NASH patient recruitment decline
- Initiating a conversation on the near-term and potential long term future of the large trials and the recruitment in them
- Analyzing the possible impacts of the first histological readouts from the current Phase 3 trials and the FDA decision on the use of surrogate markers for dual liver biopsies
- Examining ideas for the engagement of the ultimate payers into the recruitment process: the PCPs and non-hepatology specialists

Robert Riccio
Vice President, Clinical Development
Alastair Smith
Executive Medical Director
Syneos Health

11.45 Talk details to be finalized

Jeffrey Gulcher
Chief Scientific Officer & Co-Founder
WuXi NextCODE

11.45 Utility of an Accelerated Translational Model of NASH: FATZO Mouse Induced with High Fat Diet and CCl4

- Presenting a new NASH model with accelerated disease progression & exacerbated pathology
- Characterization of model and improved outcome with obeticholic acid treatment
- Demonstrating utility of new model for preclinical NASH studies

Guodong Zhang
Director of Crown Bioscience Louisiana (CBLA)
Crown Bioscience

12.00 NASH - Fibrosis & Beyond

- Recapitulating fibrosis as a key hallmark of progressive liver disease and asking the question: what it means health wise?
- Understanding how we monitoring for progression to HCC in vivo

Michael Briggs
President & Chief Scientific Officer
Woodland Biosciences

11.45 NASH Clinical Trial Design with Emphasis on Patient Recruitment

- Overview of study design for phase 3 NASH clinical trials
- Strategic considerations for patient recruitment in phase 3 trials

Star Seyedkazemi
Associate Vice President in Clinical Development
Allergan

12.15 Lunch & Networking - Lunch Seminar Hosted By: High Point Clinical Trials Center

Cross-Disciplinary Outlook on NASH Molecular Drivers & Targeting Them (Continued)

1.15 Targeting Alpha V Integrins for Liver Fibrosis

- Anti-fibrotic treatment represents an unmet medical need for patients with fibrosis diseases, such as NASH, kidney fibrosis, and IPF
- Alpha V integrins are membrane proteins that bind to latency-associated peptide (LAP) of TGF-β as its principal ligands and activate mature TGF-β to lead to fibrogenesis
- Morphic Therapeutic is leading the development of a new generation of oral drugs to target alpha V integrins for fibrotic disorders

Min Lu
Director, Head of Fibrosis
Morphic Therapeutics

Case Studies of Emerging Candidates

1.45 Targeting Integrin αVβ1 For The Treatment of Liver Fibrosis Associated With NASH

- Integrin receptors regulate multiple processes involved in inflammation, cell adhesion and fibrosis
- Av integrins are of interest as antifibrotic targets due to their role in cell-specific TGFb activation and promotion of fibrosis
- Selective targeting of specific integrins with small molecule inhibitors can interrupt the pro-fibrotic TGFb pathway, without the risks associated with systemic TGFb inhibition
- Pliant have developed oral small molecule integrin inhibitors with demonstrated antifibrotic activity in primary human liver tissue slices and preclinical models of liver fibrosis

Éric Lefebvre,
Chief Medical Officer
Pliant Therapeutics

2.15 CSTI-100, a Melanin-Concentrating Hormone Receptor 1 (MCHR1) Antagonist, for the Treatment of NASH and Metabolic Syndrome Comorbidities

CSTI-100, a selective MCHR1 antagonist addresses hallmark NASH symptoms and important related metabolic syndrome comorbidities. In preclinical models of NASH, CSTI-100 demonstrates:

- Reductions in liver triglycerides, non-esterified fatty acids and cholesterol
- Reductions in key liver inflammatory, fibrosis and injury biomarkers
- Fat selective weight loss due to a reduction in food intake
- Improvements in glucose tolerance and insulin sensitivity

Peter Guzzo
Cofounder & Chief Executive Officer
ConSynance Therapeutics

Investigating New Targets & Confirming Rationale in Human Context

1.15 Diet-Induced NHP Models of NASH & Fibrosis

Tony Wang
Chief Technology Officer
Kunming Biomed International

1.45 Using Antisense Oligonucleotides for Treatment of NASH

- Demonstrating antisense inhibition of Angptl3 as a NASH therapeutic in animal studies
- Demonstrating antisense inhibition of Keap1 as an anti-oxidant NASH therapeutic in animal studies

Richard Lee
Director
Ionis Pharmaceuticals

2.15 Methionine Aminopeptidase 2 Inhibitors as Novel Agents for Treatment of NAFLD/NASH

- Introducing MetAP2 in the context of NASH
- Showcasing efficacy in animal models of NAFLD/NASH
- Presenting clinical experience to date and translation from bench to bedside

Bryan Burkey
Head of Pharmacology
Zafgen

Strategic Considerations for Phase 3 Clinical Trials (Continued)

1.15 Role of Metabolomics in NASH Clinical Trials: A Proposal From BARC Lab/OWL

- How to provide full lab services in NASH-related clinical trials
- Strengths & Limitations of Metabolomics
- Case Study
- Looking for NASH subtyping

Pablo Ortiz
Chief Executive Officer
OWL Metabolomics
(in Partnership with BARC Lab)

Optimizing Clinical Trial Design to More Confidently Reflect Clinical Outcome

1.45 Machine Learning for Patient Selection

- Harnessing innovations in machine learning to identify and characterize NASH patients for more confident enrichment of clinical trial populations

Anthony Samir
Assistant Professor
Harvard Medical School

2.15 The HepQuant Tests as Aids to Drug Development

- HepQuant tests (HepQuant SHUNT, HepQuant FLOW, HepQuant STAT) are blood-based and minimally invasive
- The tests yield a disease severity index (DSI) of the liver's health
- STAT has favorable characteristics for use in pre-screening cases for trials
- SHUNT has favorable characteristics for tracking disease progression or response to treatment
- There are clinically significant cutoffs for DSI

Greg Everson
Chief Executive Officer
HepQuant

2.45 ROCK2 Inhibitors for the Treatment of NASH

- ROCK2 is often upregulated in diseases associated with acute and chronic inflammation, including those associated with damage caused by high glucose and high fat diets.
- Highly selective ROCK2 inhibitors developed by Redx scientists have demonstrated both anti-fibrotic and anti-inflammatory activity in preclinical *in vitro* and *in vivo* models of fibrosis.

Nicolas Guisot
Research Fellow
Redx Pharma

2.45 Anti-inflammatory & Anti-Fibrotic Effects of Icosabutate, a Structurally Engineered Fatty Acid, in Differentiated Rodent NASH Model

- Outlining the rationale behind structurally engineering of fatty acids for the treatment of liver disease
- Showcasing ADME properties of icosabutate
- Demonstrating the effects of icosabutate om inflammation and fibrosis in diverse rodent NASH models
- Sharing insights into mechanism/s of action

David Fraser
Chief Scientific Officer
NorthSea Therapeutics

2.45 Adhering to Regulatory Guidelines & Overcoming Clinical Challenges Related to NASH Proof of Concept Studies

- Filling the gap between non-invasive assessment of NASH PoC endpoints and the clinically relevant endpoints
- Robustly applying non-invasive MRI imaging in addition to liver fat quantification
- Revewing *in silico* trial simulations using 10,000 virtual NASH patients to explore and support diverse study designs
- Are there more relevant and helpful approaches in the European vs. North American current thinking in the moving target NASH development field?

Pietro Scalfaro
Chief Medical Officer
Enyo Pharma

3.15 Afternoon Refreshments & Networking

Innovations in *Ex Vivo* & Biomarkers to More Confidently Monitor Drug Efficacy

Kelsey Retting
Associate Director, Tissue Platform Operations
Organovo

4.20 Using 3D Bioprinted Human Liver Tissue to Model NAFLD/NASH in vitro

- ExVive™ Human Liver Tissue is an *in vitro* 3D bioprinted liver model containing primary human hepatocytes, hepatic stellate cells, endothelial cells, and Kupffer cells, with a complex multicellular architecture and sustained function and viability (at least 4 weeks in culture)
- Nutrient overload by addition of excess fatty acids and sugars leads to steatosis in the model, which when combined with an inflammatory stimulus can progress to hepatocellular injury, inflammation and fibrosis, characteristic of NASH
- Together, these features suggest that 3D liver tissues hold promise for the study of complex, chronic conditions such as NASH, enabling the discovery of novel therapeutics, biomarkers, and safety assessment of drugs in a disease-relevant background

SIEMENS Healthineers

4.30 An Atypical Biomarker Story - Discovery & Evolution of the Enhanced Liver Fibrosis (ELFTM) Test

- Learn about of liver fibrosis blood based biomarker panels and their differences.
- Lessons learned from the discovery and development of the ELF test.
- How the ELF test is being used today in trials and the clinic.

Counting on Combo: Investigating Pharmacotherapy to Address NASH as a Complex Pathophysiology

Resat Cinar
Co-Chair NIH Fibrosis Scientific Interest Group
National Institutes of Health

5.00 Kill two birds with one stone: MRI-1867, hybrid inhibitor of peripheral cannabinoid receptor 1 (CB1R) & inducible nitric oxide synthase (iNOS), for the treatment of NASH & liver fibrosis

- Outlining rationale for multi-target approach by polypharmacology to develop effective therapies in complex progressive diseases such as NASH and fibrotic diseases.
- Identifying dual targeting of peripheral cannabinoid receptor 1 (CB1R) & inducible nitric oxide synthase (iNOS) as an effective therapeutic strategy in obesity, diabetes, AFLD, NAFLD, NASH and liver fibrosis
- Introducing the concept of third-generation cannabinoid receptor 1 (CB1R) antagonists for metabolic and fibrotic disorders.
- Demonstrating preclinical efficacy of MRI-1867, an orally bioavailable small molecule antagonist of peripheral CB1R/iNOS, in liver fibrosis.

Nikolai Naoumov
Executive Director, Hepatology Sciences & Innovation
Novartis

5.30 Critically Reviewing Which Mechanisms of Action to Combine to Address NASH

- Understanding the rationale for combination regimes in NASH
- Exploring combination options in clinical studies and the success of combination development so far

Lou Griffel
Executive Director, Global Product Development
PPD

Dawie Wessels
Chief Medical Officer
PPD

6.00 What Are Physicians Telling Us About Their Awareness of NASH Treatment Guidelines

- Summary of our recent survey of GI specialists, primary care physicians and endocrinologists in the US about their knowledge of NASH treatment guidelines.
- Our recommendations on engaging primary care physicians and advocating for patients with advanced fibrosis to ensure they have access to novel treatment options.
- Strategies for utilizing this survey data to maximize enrollment in a crowded NASH clinical trial landscape

6.30 Chair's Closing Remarks



6.45 Scientific Poster Session

The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

"Great event, exceptional networking opportunities. High quality of presentations. Very efficient way to spend my time"

SYNEXUS

"If 150 people leave here, go out talk to their companies, their colleagues, their peers, talk about what they learnt here and make corrections: the amplification effect begins to move the field"

Intercept

Scientific Program: Wednesday April 24

Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan

8.20 Chair's Opening Remarks

Critically Assessing Patient Recruitment Challenges: Now & in the Future

Linda Morrow
Vice President & Chief Medical Officer
ProSciento

8.30 NASH/NAFLD: Does Genotype Connect to Phenotype?

- The slow rise of individualized medicine
- Genetic markers of risk for NASH/NAFLD
- Is NASH the poster child for individualized medicine?

Marko Korenjak
Vice President
European Liver Patients Association

9.00 NAFLD & NASH from the Patient Perspective - What Are Our Next Steps?

- Presenting the work of the European Liver Patients Association (ELPA)
- Outlining what can be learnt from HCV patient advocacy and policy successes
- Transferring good practice from HCV, HCC to NASH/NAFLD
- Overcoming basic problems for patients in NAFLD/NASH
- Where and how we move the field forward?

Achieving Metabolic & Hepatic Effects for the Treatment of NASH

Greg Tesz
Principal Scientist
Pfizer

9.30 The Therapeutic Potential of Inhibitors of Steatosis for the Treatment of NASH

- Demonstrating the work of the Pfizer Internal Medicine Research Unit to treat NASH by targeting the root cause of the disease, the accumulation of hepatic lipids
- Presenting the scientific rationale for targeting Diacylglycerol Transferase 2 (DGAT2) to ameliorate steatosis will be discussed
- Sharing results of DGAT2 inhibition in preclinical models of NASH will presented

10.00 Morning Break & Networking

Discovery Stream:

Chair: Robert Arch
Executive Director; Head, Liver Disease Program
China Novartis Institute for BioMedical Research

Translational Stream:

Chair: Saswata Talukdar
Director
CardioMetabolic Discovery
Merck

Clinical Stream:

Chair: Peter Traber
Partner
Alacrita Consulting

Analyzing, Quantifying & Targeting Multiple NASH Pathways

11.00 An Analysis of NASH Pathways by Single Cell Sequencing

- NASH develops through an interplay of several cell types in the liver which exist in varying abundances, although the precise nature of these interactions remains unknown
- Single Cell Sequencing (SCS) advances the sequencing capabilities of RNAseq by providing quantifiable RNA transcript reads on a single-cell basis
- By applying SCS technology to NASH and healthy liver samples, an understanding of cell-specific biology can be achieved as it relates to the pathological features of NASH

James Conway
Senior Scientist- Translational Bioinformatics
MedImmune

The Relationship of NASH in the Context of Wider Liver & Cardiovascular Disease

11.00 Combating NASH as a Metabolic, Non-Communicable Disease with Significant Global Burden

- Investigating strategies for target discovery
- Evaluating options for precision medicine

Maria-Chiara Magnone
Vice President, Metabolic Complications
Janssen Research & Development

Safety & Efficacy Within the Clinic

11.00 The Polypharmacological Anti-NASH Effects of Namodenoson are Mediated via De-Regulation of the Wnt/b-catenin Pathway

- Namodenoson is a small molecule agonist at the A3 adenosine receptor with excellent safety profile tested in >200 patients
- Definitive molecular mechanism of action including de-regulation of Wnt/b-catenin
- Current Phase 2 in NAFLD/NASH patients is on going

Pnina Fishman
Chief Executive Officer
CanFite BioPharma

11.30 Preclinical to Clinical Translation: Critically Review Quantification Methods of Liver Fat Oxidation as well as Protein Flux Biomarkers

- Exploring proteomic methods for a dynamic measurement of physiologic function and confidently quantify liver fat oxidation
- Reviewing recent progress in protein flux biomarkers as a non-invasive diagnostic
- Implementing quantification methods of liver fat oxidation and protein flux biomarkers to improve development from preclinical to clinical translation

Santhosh Satapati
Senior Scientist, Cardiovasular, Renal, Metabolic & Ophthalmic Diseases Division
Merck

11.30 Understanding Hepatocellular Carcinoma as an Extension of NASH: The Cirrhosis-HCC Connection, Practical Implications for Preclinical & Clinical Drug Testing

- Investigating cellular and molecular mechanism of fibrosis-HCC crosstalk
- Analyzing caveats of current practices of preclinical anti-fibrotic drug testing – short duration, mild disease, reliance on surrogate end-points instead of clinically-relevant long-term outcomes
- Strategizing overcoming these caveats, and how to move towards using clinically-relevant end-points in preclinical drug evaluation in practice

Yury Popov
Assistant Professor of Medicine
Harvard Medical School

11.30 Adhering to Regulatory Guidelines & Overcoming Clinical Challenges Related to NASH Proof of Concept Studies

- Filling the gap between non-invasive assessment of NASH PoC endpoints and the clinically relevant endpoints
- Robustly applying non-invasive MRI imaging in addition to liver fat quantification
- Revewing *in silico* trial simulations using 10,000 virtual NASH patients to explore and support diverse study designs
- Are there more relevant and helpful approaches in the European vs. North American current thinking in the moving target NASH development field?

Pietro Scalfaro
Chief Medical Officer
Enyo Pharma

12.00 Targeting Multiple Drivers of NASH by GSNOR Inhibition: Inflammation, Oxidative Stress, Steatosis, Glucose Dysregulation, & Fibrosis

- Regulating cellular nitrosylation through GSNOR inhibition and therefore inhibiting many drivers of pathology
- Demonstrating efficacy of SAJE's small molecule GSNOR inhibitor
- Evaluating the potential to prevent progression of NASH and, perhaps, to reverse it, and obviate the need for multiple drugs to regulate the disease

Matthews Bradley
Founder, Chairman, President & Chief Technical Officer
SAJE Pharma

12.00 The Endocrinologist Perspective: Profiling NASH in the Context of Metabolic Syndrome

- The systemic and heterogenous nature of NAFLD and its relationship to type 2 diabetes and cardiovascular disease
- Common mechanistic underpinnings

Manu Chakravarthy
Senior Vice President & Chief Medical Officer
Axcella Health

Patient Recruitment From the Perspective of the Patient

12.00 Finding NASH Patients: Uncovering Insights into the Lives of Those Who Likely Have it — But Don't Know it

- Clinical trial enrollment barriers and opportunities identified by our research study
- The patient journey — their thoughts, feelings, and emotions — leading to a better understanding for both healthcare professionals and their patients as the industry continues investigating treatment for this life-threatening condition
- How sponsor of clinical trials can more successfully engage this patient population

Cathleen Dohrn
Senior Scientific Director
Continuum Clinical

12.15 Extended Q&A

12.30 Lunch & Networking

Reviewing Clinical Advances & Regulatory Guidelines From the Last 12 Months

Frank Anania
Division of Gastroenterology & Inborn Errors Products
FDA

1.30 Regulatory Guidance on NASH Drug Development

Jason Campagna
Senior Vice President & Global NASH Lead
Intercept

2.00 Clinical Development in NASH Cirrhosis: Specifics of Cirrhotic Trials & Their Objectives

Becky Taub
Chief Medical Officer, Executive Vice President Research & Development
Madrigal Pharmaceuticals

2.30 Showcasing the Clinical Development of MGL3196

- Reviewing Madrigal's clinical development of MGL3196
- Advancing understanding surrounding thyroid hormone receptor beta agonist reducing lipotoxicity in the NASH liver
- Critically analysing MGL-3196 as the first truly beta selective THR-beta agonist

3.00 Afternoon Refreshments & Networking

Liat Hayardeny
Chief Scientific Officer
Galmed Pharmaceuticals

3.30 Aramchol Phase 2b Results & Phase 3 Outlook

- NASH develops through an interplay of several cell types in the liver which exist in varying abundances, although the precise nature of these interactions remains unknown
- Single Cell Sequencing (SCS) advances the sequencing capabilities of RNAseq by providing quantifiable RNA transcript reads on a single-cell basis
- By applying SCS technology to NASH and healthy liver samples, an understanding of cell-specific biology can be achieved as it relates to the pathological features of NASH

Dean Hum
Senior Executive Vice President & Chief Scientific Officer
Genfit

4.00 An Update of Elafibranor & Use as the Backbone for Combinations

- Overview of Elafibranor including disease model data
- Presenting data from combination program to identify synergistic mechanisms of action with Elafibranor

Laurent Fischer
Senior Vice President, Head Liver Therapeutic Area
Allergan

4.30 Chairs' Closing Remarks

"As a newcomer to the NASH space, I found the meeting to be incredibly informative and intellectually stimulating. The meeting was well organized and very comprehensive"

Inception Sciences

Discussions Day: Thursday April 25

Workshop A

Liver Fibrosis: Delineating & Utilizing the Complexities of Fibrosis Pathology

10:00am - 1:00pm

Our understanding of the paramount importance that epigenetic regulation exerts over disease progression has grown in the past decade. Not only do epigenetic mechanisms govern the course of disease, but they also inform the likelihood of ever developing disease. Importantly, epigenetic mechanisms are plastic and can be modified with in life interventions ranging from diet and exercise to use of drugs. I will highlight how epigenetic inheritance affect course of liver fibrosis development and describe the mechanisms behind these predispositions.

This workshop will discuss:

- Epigenetic mechanisms governing liver fibrogenesis, both in rodent models of disease and in patients
- DNA methylation patterns found in patient liver that show predisposition to developing liver fibrosis when exposed to chronic injury
- Hepatic DNA methylation signatures present in the circulating cell-free DNA which can be used for determining the current grade of fibrosis
- Epigenetic signatures that predispose patients towards development of fibrosis present in the liver before disease occurs

Workshop Leader:

Jelena Mann
Professor of Epigenetics, Fibrosis Research Group
Newcastle University

Workshop B

Systems Biology in NASH: Approaches & Applications

2.00pm - 5.00pm

Systems biology is an interdisciplinary field that studies the complex interactions within the liver, other tissues and oral/gut microbiota using a holistic approach. Detailed insights into the biological functions of the liver and its crosstalk with the oral/gut microbiota can be used to develop novel strategies for the prevention and treatment of NASH, and facilitate more efficient drug development decisions.

This in-depth session focuses on:

- Comprehensively analyzing the biological functions in healthy and NASH diseased states using biological network models as an integration of multiomics data
- Successfully employing systems biology in hepatology for development of efficient strategies for NASH
- Detailing how to use systems biology for simulation of liver tissue functions and its crosstalk with other tissues and microbiota for prediction of therapeutic side effects
- Understanding the systems biology of oral and gut microbiome in liver diseases.

Workshop Leader:

Adil Mardinoglu
Professor of Systems Biology
Kings College London

Discussions Day: Thursday April 25

Workshop C

Stratification of NASH Through Patient Data Sets

10.00am - 1.00pm

Stratified Medicine Scotland – Innovation Centre (SMS-IC) is focused on linking Scotland's domain expertise, data assets and delivery capability to accelerate the adoption of Precision Medicine for more effective medicine development, better diagnostics and earlier intervention, and optimal treatment selection.

Join your peers to review latest research on:

- The construction of highly curated and annotated patient data sets
- Accessing the right patient populations for stratification
- Ensuring data quality and content

Workshop Leader:

Speaker TBC
Stratified Medicine Scotland Innovation Centre

Workshop D

Drug Development Strategy & Regulatory Intelligence in NASH

2:00-5:00pm

In the last year, the NASH drug development landscape has seen the emergence of novel drug candidates and varying success in the advancement of existing candidates. Now with the very earliest NASH drug looking to hit the market in 2021, questions surrounding clinical development strategy and regulatory intelligence before and after an accepted drug are pivotal to the field.

This workshop will cover:

- Translating drug development strategies confidently into trial execution
- Reviewing the regulatory landscape currently and for the future
- The impact of the first approved NASH drug on phase 3 design (e.g. use of placebo) and utilization of biomarkers to faciliate drug development

Workshop Leader:

Richard Torstenson
Independent Regulatory Advisor

Who You'll Meet

Networking at the **3rd Annual Nash Summit** is an experience like no other and is one of the main highlights that ensures repeat attendance year on year.

With more NASH experts in attendance than any other meeting, this is your best opportunity to interact with your industry peers. Connect with **300+ attendees** across the four days through our bespoke networking experience. The summit will enable you to form real connections, gain tangible results and develop future business.

How You'll Meet Them:

Speed Networking

Your opportunity to meet valuable new contacts in a short space of time.

This session is the ideal opportunity to meet face-to face with the brightest minds working in the NASH field. Specifically designed to connect you with many new contacts.

The renowned 'Speed Networking' will be one of the most valuable hours you will spend at the NASH Summit.

Poster Sessions

Showcasing your research to a plenary of peers and investors

This session provides a key platform for you to engage in debate and rebuttal around findings and discoveries showcased in people's research.

NASH Summit App

Enhancing your ability to connect and network with fellow attendees

The NASH Summit app will enable you to easily connect with other attendees, exhibitors and speakers to arrange 1-2-1 meetings.

Download this bespoke networking app to maximize your ability to network at the conference.

300+ Attendees

150+ Organizations

12+ Hours of Networking

78% of NASH attendees are drug developers

Seniority of Attendees*

- C—Level 15%
- Vice President 18%
- Senior Director/ Director 30%
- Team Leader/ Project Manager 24%
- Principal Scientist/ Scientist 11%
- Academic 2%

Attendees by Company

- Large Drug Developer
- Small & Medium Drug Developer
- Technology & Service Provider
- Research Institute
- Consultant



Attendance by Geo



- Europe 13%
- North America 81%
- Asia 6%

* Based upon the 2nd Annual NASH Summit Boston (2018)

Tel: +1 617 455 4188 Email: info@hansonwade.com
www.nash-summit.com Nonalcoholic Steatohepatitis (NASH) Group

hansonwade

Our Partners 2019

Lead Partner

ICON

Senior Partners

PPD

prosciento
ADVISE • ADVANCE • ACHIEVE

SIEMENS Healthineers

Program Partners

Barc Lab

HEPQUANT
FUNCTION MATTERS

KBI

Syneos Health

WuXiNextCODE

Spotlight Partners

CrownBio
CONNECTING SCIENCE TO PATIENTS

CONTINUUM CLINICAL

organovo

WOODLAND BIOSCIENCES

Hosting Partner

HIGH POINT
CLINICAL TRIALS CENTER

Exhibition Partners

diapharma

JUBILANT BIOSYS

OracleBio
Image Analysis Solutions

PROMETHEUS
Therapeutics & Diagnostics
For the person in every patient
A Nestlé Health Science Company

Partners

The Jackson Laboratory
Leading the search for tomorrow's cures

SYNEXUS

BECOME A PARTNER

Jakub Nunuk
Partnership Manager
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.nash-summit.com/register

Tel: +1 617 455 4188

register@hansonwade.com

"Very professional staff, and very helpful throughout the conference. Organized and relevant to understanding pipeline product development in NASH and the marketplace better"

Kowa

3 Key Takeaways From Attending:

1. An understanding of commercialization including the paying and reimbursement landscape and challenges for placebo controlled phase 3 trials once the first generation of drugs are approved
2. An understanding of the non-invasive diagnostics landscape and regulatory perspective on biomarker adoption for clinical trials
3. An understanding of scientific rationale of combinational therapeutics as the necessary treatment strategy for NASH to inform pairing decisions

Send a Group to Benefit from:

Maximize your learning opportunity

Ensure you've met with all potential and new partners, existing collaborators and colleagues

Get value for money using special team discounts

- 20% discount – 5 or more delegates
- 15% discount – 4 delegates
- 10% discount – 3 delegates

Secure Your Place

Standard Rate	Register & Pay before Friday, March 8	Standard Prices
Gold Pass: Full Access - Scientific Program & Seminar Day & Discussion Day	$4447 **(save $1250)**	$4547 **(save $1150)**
Silver Pass: Scientific Program plus Seminar Day or Discussion Day (For Discussion Day - Choose from A or C AND B or D)	$3698 **(save $600)**	$3898 **(save $400)**
Bronze Pass: Scientific Program only	$2699 **(save $200)**	$2899
Seminar Day Only (Pre-conference)	$1399	
Discussion Day Only (Workshops) (Choose from A or C AND B or D)	$1399	

*Academics are entitled to a 40% discount off the Industry Pricing
(Please note: Discounts cannot be combined with any other offer)

*VAT charged at 19%





Venue

Hilton Boston Logan Airport
1 Hotel Dr, Boston, MA 02128, USA

For further information or assistance, please visit
www3.hilton.com